bindarit   Click here for help

GtoPdb Ligand ID: 11124

Synonyms: AF-2838 | AF2838
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Bindarit is a compound with anti-inflammatory activity. In vitro, that is primarily associated with an inhibition of MCP-1 (CCL2) production and subsequent reduction in monocyte recruitment and differentiation. It has been shown to directly interact with fatty acid binding protein 4 (FABP4) and this is proposed to underlie its mechanism of action [1]. In this mechanism bindarit modulates the phosphorylation state of p38α and AKT2 and selectively increases FABP4 expression, all in a PPARγ-dependent manner, and these effects are associated with a decrease in MCP-1 production.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 64.35
Molecular weight 324.15
XLogP 3.34
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES OC(=O)C(OCc1nn(c2c1cccc2)Cc1ccccc1)(C)C
Isomeric SMILES OC(=O)C(OCc1nn(c2c1cccc2)Cc1ccccc1)(C)C
InChI InChI=1S/C19H20N2O3/c1-19(2,18(22)23)24-13-16-15-10-6-7-11-17(15)21(20-16)12-14-8-4-3-5-9-14/h3-11H,12-13H2,1-2H3,(H,22,23)
InChI Key MTHORRSSURHQPZ-UHFFFAOYSA-N
Immunopharmacology Comments
Bindarit is an orally bioactive anti-inflammatory compound, that inhibits the production of certain C-C motif chemokines, such as MCP-1 (CCL2). It thereby interferes with monocyte recruitment and differentiation. Safety of bindarit in humans has been demonstrated in clinical trials. Elevated levels of CCL2 and proinflammatory monocyte infiltration are associated with persistent periodontal inflammation, such as observed in diabetes-associated periodontitis (DP). Bindarit-induced Inhibition of CCL2 has been proposed as a therapeutic option for DP [2].